The on-target off-tumour toxicities of T-cell-engaging bispecific antibodies in patients can be captured in intestinal organoids derived from the patients’ biopsied tissue and supplemented with immune cells.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Nat Biotechnol. 32, 40–51 (2014).
Clevers, H. Cell 165, 1586–1597 (2016).
Schnalzger, T. E. et al. EMBO J. 38, e100928 (2019).
Gonzalez-Exposito, R. et al. J. Immunother. Cancer 7, 101 (2019).
Harter, M. F. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01156-5 (2023).
Xu, H. et al. Exp. Hematol. Oncol. 7, 30 (2018).
Votanopoulos, K. I. et al. Ann. Surg. Oncol. 27, 1956–1967 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.G. receives institutional research funding from Bristol Myers Squibb, Merck KG and Roche, speaker fees from Bristol Myers Squibb and Merck KG, and expert advisory fees from Merck Sharp and Dohme and Roche.
Rights and permissions
About this article
Cite this article
Buzzetti, M., Gerlinger, M. Assessing the toxicity of bispecific antibodies. Nat. Biomed. Eng 8, 339–340 (2024). https://doi.org/10.1038/s41551-023-01163-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-023-01163-6